This randomised, triple-blind, placebo-controlled crossover trial (n=18) will investigate the acute analgesic (anti-pain) effects of N,N-dimethyltryptamine (DMT) on experimentally induced acute nociceptive pain, hyperalgesia, and allodynia in healthy participants.
N,N-dimethyltryptamine (DMT), a classical psychedelic, has shown promise in treating pain-related conditions, but rigorous clinical trials are lacking. The study aims to evaluate DMT’s efficacy in managing different pain qualities, using a validated electrical stimulation model in healthy volunteers. Participants will receive intravenous infusions of DMT, racemic ketamine (active control), or placebo on separate days in a randomised, counter-balanced order.
The primary outcome measure is the difference in cumulative Numeric Rating Scale (NRS) scores (0 – 10) between DMT, ketamine, and placebo conditions during infusion. Secondary outcome measures include assessing areas of hyperalgesia and allodynia, subjective effect ratings, plasma levels of DMT and ketamine, and their association with personality traits.
This study, sponsored by University Hospital, Basel, Switzerland, is expected to commence in May 2024 and conclude by February 2025. Participants must be aged between 25 and 75 years, proficient in German, willing to adhere to study procedures, and refrain from consuming illicit psychoactive substances during the study period. Exclusion criteria include major medical or psychiatric disorders, hypertension/hypotension, recent hallucinogenic/dissociative substance use, pregnancy, and participation in other clinical trials.
Trial Details
Trial Number
Sponsors & Collaborators
University of BaselThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.